Year: 2024

Blueback

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)

CI

Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau

HONG KONG--(BUSINESS WIRE)--Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is...

logo-32

South Korea Data Center Market Investment Analysis Report 2024-2029: Opportunities in IT, Electrical, Mechanical Infrastructure, General Construction, and Tier Standards – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "South Korea Data Center Market - Investment Analysis & Growth Opportunities 2024-2029" report has been added to ResearchAndMarkets.com's...